6/19
10:33 am
mcrb
Human Microbiome Market Forecasts Report 2025-2030: Key Insights for Navigating Emerging Opportunities [Yahoo! Finance]
Low
Report
Human Microbiome Market Forecasts Report 2025-2030: Key Insights for Navigating Emerging Opportunities [Yahoo! Finance]
6/12
05:50 pm
mcrb
4 Emerging Graft versus Host Disease Therapies That Could Change the Treatment Landscape | DelveInsight [Yahoo! Finance]
Medium
Report
4 Emerging Graft versus Host Disease Therapies That Could Change the Treatment Landscape | DelveInsight [Yahoo! Finance]
6/5
08:12 am
mcrb
$1.2 bN Human Microbiome-based Drugs and Diagnostics Global Markets, 2022-2024 & 2025-2030 [Yahoo! Finance]
Low
Report
$1.2 bN Human Microbiome-based Drugs and Diagnostics Global Markets, 2022-2024 & 2025-2030 [Yahoo! Finance]
5/27
07:20 am
mcrb
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting [Yahoo! Finance]
Medium
Report
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting [Yahoo! Finance]
5/27
07:00 am
mcrb
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
Medium
Report
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
5/9
03:37 am
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
5/9
03:37 am
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
5/8
08:02 am
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "neutral" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock, up previously from $1.25.
High
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "neutral" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock, up previously from $1.25.
5/7
07:00 am
mcrb
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
Low
Report
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
5/1
01:11 am
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
4/29
07:24 am
mcrb
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases [Yahoo! Finance]
Low
Report
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases [Yahoo! Finance]
4/29
07:00 am
mcrb
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
Low
Report
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
4/23
11:18 pm
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
4/23
07:00 am
mcrb
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
High
Report
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025